Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Jul 19, 2021

SELL
$1.69 - $2.85 $489,669 - $825,773
-289,745 Closed
0 $0
Q1 2021

Apr 27, 2021

BUY
$1.81 - $3.88 $5,672 - $12,159
3,134 Added 1.09%
289,745 $765,000
Q3 2020

Nov 03, 2020

SELL
$1.58 - $2.37 $21,154 - $31,731
-13,389 Reduced 4.46%
286,611 $499,000
Q2 2020

Aug 03, 2020

BUY
$1.16 - $2.61 $348,000 - $783,000
300,000 New
300,000 $654,000

About Akari Therapeutics Plc


  • Ticker AKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,349,200
  • Market Cap $165M
  • Description
  • Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-...
More about AKTX
Track This Portfolio

Track United Asset Strategies, Inc. Portfolio

Follow United Asset Strategies, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of United Asset Strategies, Inc., based on Form 13F filings with the SEC.

News

Stay updated on United Asset Strategies, Inc. with notifications on news.